Saturday, 31 October 2026European Markets

TOYOTA CAETANO And SMURFIT KAPPA GP Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(VIANEWS) - TOYOTA CAETANO (SCT.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Cyclical sector.

Financial Asset Price Forward Dividend Yield Return on Equity
TOYOTA CAETANO (SCT.LS) €5.90 4.27% 9.52%
SMURFIT KAPPA GP (SK3.IR) €42.57 3.33% 14.31%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. TOYOTA CAETANO (SCT.LS)

4.27% Forward Dividend Yield and 9.52% Return On Equity

Toyota Caetano Portugal, S.A. imports, assembles, and commercializes light and heavy vehicles. It offers commercial and passenger cars, as well as parts; cargo handling machines; and mini-buses. The company also sells and rents industrial equipment, including counterweight forklift trucks and warehouse equipment; provides technical after-sales assistance; incorporates components into commercial vehicles; and offers business services and solutions, such as short-term rental, used and reconditioned assistance, maintenance contracts sale of parts, and fleet management of related equipment. It distributes its products under the Toyota and Lexus brand names in Portugal, Belgium, African countries, Spain, Germany, the United Kingdom, and internationally. The company was incorporated in 1946 and is headquartered in Vila Nova de Gaia, Portugal. Toyota Caetano Portugal, S.A. is a subsidiary of Salvador Caetano Auto (S.G.P.S.), S.A.

Earnings Per Share

As for profitability, TOYOTA CAETANO has a trailing twelve months EPS of €0.55.

PE Ratio

TOYOTA CAETANO has a trailing twelve months price to earnings ratio of 10.73. Meaning, the purchaser of the share is investing €10.73 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.52%.

Volatility

TOYOTA CAETANO's last week, last month's, and last quarter's current intraday variation average was 5.39%, 2.00%, and 6.80%.

TOYOTA CAETANO's highest amplitude of average volatility was 8.63% (last week), 7.86% (last month), and 6.80% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 485.44M for the twelve trailing months.

Moving Average

TOYOTA CAETANO's worth is higher than its 50-day moving average of €5.40 and way higher than its 200-day moving average of €4.43.

More news about TOYOTA CAETANO.

2. SMURFIT KAPPA GP (SK3.IR)

3.33% Forward Dividend Yield and 14.31% Return On Equity

Smurfit Kappa Group Plc, together with its subsidiaries, manufactures, distributes, and sells containerboard, corrugated containers, and other paper-based packaging products in Ireland, Germany, France, Mexico, rest of Europe, and other Americas. The company offers e-commerce, retail, consumer, industrial, bottle, protective, heavy-duty, hexacomb, and various punnet packaging products; composite cardboard tubes, bags, and sacks; and bag-in-box, a packaging system that comprises films, accessories, bags, taps, and boxes. It also provides point of sale displays; cardboards of social distancing; corrugated sheet boards, solid board sheets, folding carton sheet boards, sack Kraft papers, MG brown Kraft papers, preprint products, agro-papers, technical papers, BanaBag, and Catcher Board MB12; and various types of containerboards, such as kraftliners, testliners, and containerboard flutings. In addition, the company offers recycling solutions to cardboard and paper products; and supplies packaging machinery. It primarily serves consumer goods, industrial goods, and food and drink sectors. Smurfit Kappa Group Plc was founded in 1934 and is headquartered in Dublin, Ireland.

Earnings Per Share

As for profitability, SMURFIT KAPPA GP has a trailing twelve months EPS of €2.91.

PE Ratio

SMURFIT KAPPA GP has a trailing twelve months price to earnings ratio of 14.63. Meaning, the purchaser of the share is investing €14.63 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.31%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SMURFIT KAPPA GP's stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.5%, now sitting on 11.27B for the twelve trailing months.

Yearly Top and Bottom Value

SMURFIT KAPPA GP's stock is valued at €42.57 at 22:30 EST, under its 52-week high of €45.60 and way higher than its 52-week low of €28.98.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Apr 11, 2024, the estimated forward annual dividend rate is 1.52 and the estimated forward annual dividend yield is 3.33%.

More news about SMURFIT KAPPA GP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com